Gastrointestinal (pancreas) Cancer: Glufosfamide Versus 5-FU in Second Line Metastatic
Will the study drug (Glufosfamide) work as well as Fluorouracil (5-FU), the approved
treatment, in treating pancreatic cancer?
Basic Study Information
Purpose:Location: Cancer Center
Glufosfamide is being compared against Fluorouracil (5-FU). Fluorouracil is approved
by the FDA for use in people with rectal cancer. 5-FU was the drug of choice for pancreatic
cancer before gemcitabine and is still used in multiple regimens such as folfox and
Folfirinox as part of standard of care.
The study drug is made of glucose (a sugar made by the body) and a substance which
damages or kills cancer cells. Cancer cells depend on sugar more than normal cells
do, so the cancer cells may take up more of the study drug than normal cells. This
may allow glufosfamide to attack the cancer cells without causing excessive damage
to the normal cells.
Study Web URL: http://clinicaltrials.gov/ct2/show/NCT01954992?term=Glufosfamide+Compared+with+Fluorouracil&rank=1
Study Reference #: IGIP-14032
Lead Researcher (Principal Investigator)
Lead Researcher: Marcus Noel
Study Contact InformationStudy Coordinator: Chris LeFeber
Phone: (585) 275-0407
Additional Study Details
Learn More About These Conditions
More information about Pancreatic Cancer
Trial Not Found
The study you are looking for is not active at this time.
Return to Search